Al Altomari, Chairman and CEO
Agile Therapeutics
Margaret Anderson, Managing Director
Deloitte
Charlene Banard, Former Head of Quality, Technical Operations
Shire
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chief Operating Officer
Beyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Joseph Ferra, CFO
Syros Pharmaceuticals
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., SVP Oncology R&D
GSK
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Mitchell Katz, Ph.D., Vice President, Development Operations
Ferring Pharmaceutical, Inc.
Mary Rose Keller, VP, Clinical Operations
Heron Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Health
Jacks Lee, SVP global manufacturing and supply
Merck
Martin Lehr, CEO
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, President & CEO
Cognition Therapeutics
Bernard Munos, Founder
InnoThink Center for Research in Biomedical Innovation
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Julia Owens, Ph.D., President and CEO
Millendo Therapeutics
Sandra Poole, Member Board of Directors
Retrophin and ViaCyte
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
John Reynders, Ph.D., VP, R&D strategy, program management, and data sciences
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Tomasz Sablinski,M.D., Ph.D., Cofounder & CEO
Transparency Life Sciences
Chhaya Shah, SVP Technical Operations
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, President and CEO
Navigen
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
Jason Urban, Ph.D., Head of External Engagement
Bristol-Myers Squibb
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Founder, President & CEO
ImmusanT

IN THIS MONTH'S ISSUE

  • The Bipartisan Dismemberment Of The ACA

    Hours after the House of Representatives impeached President Donald J. Trump, it passed a gargantuan omnibus appropriation package costing $1.4 trillion in 2020 that continues the bipartisan unravelling of the Affordable Care Act (i.e., Obamacare) by repealing three taxes critical to its financing: the “Cadillac tax” on high-cost insurance plans, the medical device excise tax, and the health insurance tax. Together, their repeal costs the federal government $373.3 billion in lost revenue over the next 10 years according to the Joint Committee on Taxation.

  • Women On Boards: How We Get From Here To There

    Even though females have “arrived” as biotech executives, there’s more to be done: serving as CEOs, advisors, and directors to help companies achieve their missions.

  • A Small Biopharma That Doesn’t Use CROs

    When it comes to conducting clinical trials, most emerging companies choose to access external resources through partnering with CROs. That is what makes Martin Lehr, CEO of Context Therapeutics different. He prefers to bypass CROs and take part in Investigator-Sponsored Trials (ISTs).

  • How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

    If you’re a senior biopharma executive, your best industry bet is to incorporate compliance into your highest-level strategic planning as early as possible. Doing so will ultimately benefit the company, come rain or shine.

  • How To Overcome The Challenge Of Valuing A Biotech

    Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.

@LIFESCILEADER1

 EVENTS